T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (421)	4/11/2001 1:44:30 PM
From: scaram(o)uche	Read Replies (1) of 2243

I'll take a look. I only remember them from a Biogen license for Hirulog, a thrombin inhibitor. Is that Angiomax? If so, I wouldn't expect it to be a blockbuster. I don't remember the details, but it failed in trials versus heparin for Biogen. Not saying that it's not a good investment. The double negative there is intentional. It sounds much more full of punch than "not saying that it's a bad investment". That is..... a little knowledge can be a very bad thing, and I have very little knowledge on this front. Oral thrombin inhibitor...... anyone know the guidance re. royalty rate, Centocor to DDDP?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next